CGT Landscape: Recent Approvals, Deals And 2024 Catalysts

 
• By Lucie Ellis-Taitt

The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline. 

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
• Source: Shutterstock

More from Deal-Making

More from In Vivo